UK Community Advisory Board (UK-CAB)

UK-CAB 34 – Training: clinical trials and databases

Friday 18 June 2010

At the MRC Clinical Trials Unit, 222 Euston Road, London, NW1

09:30–10:00 Registration, refreshments and expenses
10:00–10:15 Welcome, introductions and UKCAB updates
10:15–10.45 Introduction: What are observational studies, and how do they differ from clinical trials? – Caroline Sabin, Professor of Medical Statistics and Epidemiology Royal Free & University College Medical School
10:45–11:05 The UK Collaborative HIV Cohort Study (UK CHIC) – Caroline Sabin/Loveleen Bansi
11:05–11:25 The UK HIV Drug Resistance Database – David Dunn, Clinical Trials Unit, MRC
11:25–11:40 Break
11.40–12.00 National Study of HIV in Pregnancy and Childhood (NSHPC) – Pat Tookey, Senior Lecturer, MRC Centre of Epidemiology for Child Health, UCL Institute of Child Health
12.00–12.20 The Collaborative HIV Paediatric Study (CHIPS) – Pat Tookey
12:20–12:40 HPA Surveillance databases – Dr Sam Lattimore
12:40–14:00 Lunch
14:00–15:00 Community Discussion – Simon Collins
15.00–15.15 Break
15:15–15.45 New IT methods to protect data and how are they being used? – Nathan Lea, Research Fellow, UCL Centre For Health Informatics & Multiprofessional Education (CHIME)
15.45–16:15 How do we analyse observational databases and what biases do we have to be aware of? – Caroline Sabin/David Dunn
16.15 Close

Background Reading

Clinical trials and databases

Main types of trial design

Other types of studies:

Patient Involvement in clinical studies and research

Summary of different advocacy roles

Glossary of other terms:



UK HIV Drug Resistance Database

National Study of HIV in Pregnancy and Childhood (NSHPC)

The Collaborative HIV Paediatric Study (CHIPS)

HPA Surveillance databases

Financial support

The UK-CAB receives unrestricted funding from some pharmaceutical companies towards the direct costs of holding four meetings each year. This funding supports the travel and accommodation costs for members to attend from outside London, plus the cost of catering.

The content, programme and agenda for meetings is decided by the UK-CAB steering group in consultation with the wider membership. Funding is unconnected to meeting content.

We believe that manufacturers who currently develop and market medicines have a responsibility to actively engage with advocacy organisations and that HIV positive people and their advocates should be able to directly question manufacturers about the safety and efficacy of their products and proposals for future research.

For a list of companies that support the UK-CAB please see the “about us” page.